跳至主要内容
临床试验/CTRI/2023/09/057273
CTRI/2023/09/057273尚未招募Unknown

Identification of resistance and response markers to immuno-oncology drugs. - NI

Strand Life Sciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients with confirmed malignant carcinoma as defined above who are eligible for mono-immuno-oncology therapy and will undergo the treatment, as identified by the site Principal Investigator or Co-Investigators through routine clinical care processes
  • Age - 18 years and above
  • Both men and women of all races and ethnic groups are eligible for this study
  • New, relapsed, recurrent or metastatic cases
  • Ability to understand and the willingness to sign a written Informed Consent Form

排除标准

  • Pregnant or lactating women
  • Patients who have untreated active infection
  • Patients who are receiving any additional oncology investigational agent(s) with immuno-oncology drugs
  • Patients undergoing combinatorial immunotherapy

研究者

发起方
Strand Life Sciences Pvt Ltd

相似试验